23andMe is grappling with significant challenges following a major data breach last year that compromised sensitive information for nearly half of its customer base. The aftermath has been turbulent, with the company agreeing to a $30 million settlement in a class-action lawsuit and shuttering its in-house drug discovery unit in August. Compounding these issues, a mass resignation of board members has ensued over CEO Anne Wojcicki’s strategic choices, particularly her controversial proposal to take the company private at a substantially lower valuation than expected. These developments have cast doubt on the company’s future direction.
Once valued at $6 billion when it went public in 2021, 23andMe’s stock has since nosedived from $10 per share to a fraction of its original price. After 18 years in operation, the company is still struggling to achieve profitability. The dip in demand for at-home DNA testing kits, which began in 2019, has exacerbated the company’s woes. With many customers already having explored their ancestry and health risks, 23andMe is now facing a saturated market and stiffer competition.
In a bid to reignite interest, the company introduced premium services, offering more comprehensive genetic reports and health recommendations. However, these efforts have yet to significantly bolster its revenue. While 23andMe has diversified its membership options, including services like Total Health, many consumers are reluctant to commit to ongoing subscriptions after their initial experience. The consensus appears to be that, once users gain insights into their family history and health risks, there is little incentive to maintain a long-term engagement.
To diversify its revenue streams, 23andMe once allowed pharmaceutical companies access to its genetic database, securing partnerships with firms like GlaxoSmithKline. But with the expiration of those agreements and no new significant partnerships on the horizon, the company has shifted its focus to expanding telehealth services. Its 2021 acquisition of Lemonaid enabled 23andMe to offer weight-loss management and other health services, but the telehealth market is crowded and competitive, posing new challenges to its growth strategy.
Another critical hurdle is the erosion of trust. The data breach exposed sensitive information of nearly 7 million users
